Related Experiment Video
Updated: Mar 29, 2026

08:00
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
19.6K
Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study
Isabelle Pinheiro Amaro de Magalhães1, Camila Regina Pereira Batista de Macedo1, Luciana Ansaneli Naves2
1Neuroendocrinology Unit, Division of Metabolism and Endocrinology, Department of Internal Medicine, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Pituitary
|March 27, 2026
Abstract
No abstract available in PubMed .
Keywords:
Aggressive pituitary adenoma, pituitary carcinomaMGMTPituitary neuroendocrine tumorsTemozolomideMore Related Videos
Related Concept Videos
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers
1.5K
1.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
818
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
818

